Title : ANGPTL4 suppresses clear cell renal cell carcinoma via inhibition of lysosomal acid lipase - Jin_2024_Cancer.Res.Commun__ |
Author(s) : Jin Z , De U , Tithi TI , Kleberg J , Nataraj A , Jolley E , Carelock ME , Davies BS , Zhang W , Kolb R |
Ref : Cancer Research Commun , : , 2024 |
Abstract :
Renal cell carcinoma (RCC), the most common form of kidney cancer, is a heterogeneous disease with clear cell RCC (ccRCC) being the most prevalent and aggressive subtype. While most ccRCC tumors have elevated expression of angiopoietin-like 4 (ANGPTL4), in our study we identified a significant subset of patients whose cancers show no increase in ANGPTL4 expression. These patients have a worse prognosis compared to the patients with high expression of ANGPTL4. These ANGPTL4-low cancers are characterized by the increased frequency of wild-type Von Hippel-Lindau (wt VHL), a gene that is commonly mutated in ccRCC, and an enrichment for genes associated with lipid metabolism. Using RCC tumor models with wild type VHL, we demonstrate that ANGPTL4 behaves as a tumor suppressor. The loss of ANGPTL4 in ccRCC cell lines results in increased tumor growth and colony formation in a lysosomal acid lipase (LAL)-dependent manner, a phenotype rescued by the expression of N-terminus ANGPTL4. At the mechanistic level, the loss of ANGPTL4 increases lysosomal acid lipase activity in ccRCC cells. This data suggests that ANGPTL4 enacts its tumor-suppressive effects in ccRCC by regulating LAL activity. Importantly, the identified patient cohort with low ANGPTL4 expression may exhibit increased reliance on lipid metabolism, which can be a point of target for future therapy. |
PubMedSearch : Jin_2024_Cancer.Res.Commun__ |
PubMedID: 39105498 |
Jin Z, De U, Tithi TI, Kleberg J, Nataraj A, Jolley E, Carelock ME, Davies BS, Zhang W, Kolb R (2024)
ANGPTL4 suppresses clear cell renal cell carcinoma via inhibition of lysosomal acid lipase
Cancer Research Commun
:
Jin Z, De U, Tithi TI, Kleberg J, Nataraj A, Jolley E, Carelock ME, Davies BS, Zhang W, Kolb R (2024)
Cancer Research Commun
: